A review of the use of psychotropic medication in pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 23, Issue 6, 2011, Pages 408-414

  Galbally, Megan ^a   Snellen, Martien ^a   Lewis, Andrew J ^b  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

antidepressants; antipsychotics; mood stabilizers; pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; FLUOXETINE; FOLIC ACID; LAMOTRIGINE; LITHIUM CARBONATE; NORADRENALIN UPTAKE INHIBITOR; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

BIPOLAR DISORDER; BIRTH DEFECT; COGNITIVE DEFECT; CONGENITAL MALFORMATION; DIARRHEA; EBSTEIN ANOMALY; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; MENTAL DISEASE; NERVOUSNESS; NEURAL TUBE DEFECT; PERSISTENT PULMONARY HYPERTENSION; PREECLAMPSIA; PREGNANCY; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SEROTONIN SYNDROME; SIDE EFFECT; SPONTANEOUS ABORTION; TOXICITY; VOMITING;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; MENTAL DISORDERS; MOOD DISORDERS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTROPIC DRUGS; RISK ASSESSMENT;

EID: 81255169942     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32834b92f3     Document Type: Review

References (62)

1. Bennedsen B, Mortensen P, Olesen A, et al. Obstetric complications in women with schizophrenia. Schizophrenia Res 2001; 47:167-175.
2. Nilsson E, Hultman CM, Cnattingius S, et al. Schizophrenia and offspring's risk for adverse pregnancy outcomes and infant death. Br J Psychiatry 2008; 193:311-315.
3. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162:79.
4. Bansil P, Kuklina EV, Meikle SF, et al. Maternal and fetal outcomes among women with depression. J Women's Health 2010; 19:329-334.
5. Brettingham M. Depression and obesity are major causes of maternal death in Britain. Br Med J 2004; 329:1205.
6. Austin MP, Kildea S, Sullivan E. Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med J Aust 2007; 186:364-367.
7. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359:61-73.
8. O'Connor TG, Heron J, Golding J, et al. Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years: report from the Avon longitudinal study of parents and children. Br J Psychiatry 2002; 180:502.
9. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG 2008; 115:1043-1051.
10. Hay DF, Pawlby S, Waters CS, Sharp D. Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes. J Child Psychol Psychiatry 2008; 49:1079-1088.
11. Hay DF, Pawlby S, Waters CS, et al. Mothers' antenatal depression and their children's antisocial outcomes. Child Dev 2010; 81:149-165.
12. O'Connor TG, Ben-Shlomo Y, Heron J, et al. Prenatal anxiety predicts individual differences in cortisol in preadolescent children. Biol Psychiatry 2005; 58:211-217.
13. Spitzer RL, Williams JBW, Kroenke K, et al. Validity and utility of the PRIMEMD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol 2000; 183:759-769.
14. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005; 106 (5 Pt 1):1071-1083.
15. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157:179-184.
16. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. J Am Med Assoc 2006; 295:499-507.
17. Cooper WO, WillyME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196:544e1-544e5.
18. Fisher B, Rose NC, Carey JC. Principles and practice of teratology for the obstetrician. Clin Obstet Gynecol 2008; 51:106-118.
19. Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 2011; 123:266-275.
20. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010; 44:978-996.
21. Toh S, Mitchell AA, Louik C, Werler MM, et al. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 2009; 166:320-328.
22. Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95:487-490.
23. Dubnov-Raz G, Juurlink DN, Fogelman R, et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 2008; 122:e710-e715.
24. Rounds M. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can 2009; 31:452-456.
25. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can Med Assoc J 2010; 182:1031.
26. Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005; 25:595-604.
27. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatric Adolesc Med 2009; 163:949-954.
28. Ramos E, St-Andre M, Berard A. Association between antidepressant use during pregnancy and infants born small for gestational age. Can J Psychiatry 2010; 55:643-652.
29. Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007; 164:1206-1213.
30. Lewis AJ, Galbally M, Opie G, Buist A. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 2010; 44:482-487.
31. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579-587.
32. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17:801-806.
33. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18:246-252.
34. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84:23-27.
35. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011; 28:19-24.
36. This is the fifth study to examine the association between PPHN and late pregnancy SSRI antidepressant exposure. This study found that PPHN was associated with caesarean section not SSRI exposure in a case-controlled study.
37. Hernandez-Diaz S, Van Marter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120:e272.
38. Reece EA, Moya F, Yazigi R, et al. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet Gynecol 1987; 70:696.
39. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-1015.
40. Galbally M, Lewis AJ, Lum J, Buist AE. Serotonin discontinuation syndrome following in-utero exposure to antidepressant medication: a prospective controlled study. Aust N Z J Psychiatry 2009; 43:846-854.
41. Warburton W, Hertzman C, Oberlander T. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010; 121:471-479.
42. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011; 128:1-9.
43. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142:402-408.
44. Mortensen JT, Olsen J, Larsen H, et al. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and antiepileptics. Eur J Epidemiol 2003; 18:769-771.
45. Galbally M, Lewis AJ, Buist A. Developmental outcomes of children exposed to antidepressants in pregnancy. Aust N Z J Psychiatry 2011; 45:393-399.
46. Yonkers KA, Wisner KL, Stewart D'E, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynaecologists. Obstet Gynecol 2009; 114:703-713.
47. Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG 2009; 116:758-767.
48. Galbally M, Roberts M, Buist A. Mood stabilizers in pregnancy: a systematic review. Aust N Z J Psychiatry 2010; 44:967-977.
49. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. J Am Med Assoc 2011; 305:1996-2002.
50. Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011. doi: 10.1136/adc.2009.176990. [Epub ahead of print]
51. Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J of Psychiatry 2010; 44:99-108.
52. Koren G. Medication safety in pregnancy and breastfeeding: McGraw-Hill Professional; 2007.
53. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162:79-91.
54. Snellen M, Mack K, Trauer T. Schizophrenia, mental state, and mother-infant interaction: examining the relationship. Aust N Z J Psychiatry 1999; 33:902-911.
55. Riordan D, Appleby L, Faragher B. Mother-infant interaction in postpartum women with schizophrenia and affective disorders. Psychol Med 1999; 29:991-995.
56. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. Journal of Psychiatric Practice 2009; 15:183.
57. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36:518-544.
58. Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008; 192:333-337.
59. Babu GN, Desai G, Tippeswamy H, Chandra PS. Birth weight and use of olanzapine in pregnancy: a prospective comparative study. J Clin Psychopharmacol 2010; 30:331-332.
60. FDA. FDA Drug Safety Communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. US Food and Drug Administration; 2011. https://www.fda.gov/Drugs/DrugSafety/ucm243903.htm. [Accessed 17 June 2011]
61. Robertson E, Grace S, Wallington T, Stewart D'E. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry 2004; 26:289-295.
62. Murray L, Cooper PJ, Wilson A, Romaniuk H. Controlled trial of the short- and long-term effect of psychological treatment of postpartum depression. 2: Impact on the mother-child relationship and child outcome. Br J Psychiatry 2003; 182:420-427.